Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided wherein R1-R6 and X are defined herein. Also provided are methods of preparing the compounds of formula (I) pharmaceutical compositions and kits containing a compound of formula (I) as are methods of treating endometriosis hormone-dependent carcinomas leiomyoma fibroids dysfunctional bleeding polycystic ovary syndrome and menopause related symptoms; methods of contraception; methods of providing hormone replacemen...

Methods of preparing and purifying 9-nitrominocycline and 9-aminominocycline and salts thereof used in the process of making tigecycline are disclosed. In one embodiment the invention is directed to a method of preparing the compound of formula 1 or a pharmaceutically acceptable salt thereof comprising: (a) reacting nitric acid with the compound of formula 2 or a salt thereof to produce a reaction mixture comprising an intermediate; and (b) further reacting the intermediate to form the compound ...

The present invention provides 4-aminoquinoline 3-carbonitirle compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.

Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1 R2 R3 R4 R5 and Q1 are defined herein.

Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives of formula I are provided:wherein: R1 R2 R3 R4 and R5 are as defined herein which are useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease and pulmonary fibrosis.

The present invention provides compounds and compositions and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders diseases and conditions. Provided compounds can affect among other things neurological psychiatric and/or inflammatory systems.

The present invention provides methods for treating MDD. In general the methods comprise administering to a patient in need thereof a daily dose of about 50 mg ODV or an equivalent amount of a pharmaceutically acceptable salt thereof. In certain embodiments a patient in need of treatment is characterized by a primary diagnosis of MDD. In some embodiments the dose is administered as a single daily dose. In one set of embodiments the methods involve administering an oral dosage form comprising the...

Thioamide compounds and specifically thioamide pyrrole compounds and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators in contraception and in the treatment of progesterone-related maladies.

Methods of preparing and purifying 9-nitrominocycline and 9-aminominocycline and salts thereof used in the process of making tigecycline are disclosed. In one embodiment the invention is directed to a method of preparing the compound of formula 1 or a pharmaceutically acceptable salt thereof comprising: (a) reacting nitric acid with the compound of formula 2 or a salt thereof to produce a reaction mixture comprising an intermediate; and (b) further reacting the intermediate to form the compound ...

A novel salt of O-desmethyl venlafaxine is provided O-desmethylvenlafaxine succinate. Pharmaceutical compositions dosage forms and methods of use are also provided.